1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
1606 Corp. (OTC Pink:CBDW), an AI technology developer, has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a leading AI biotech company. This potential investment aims to expand 1606 Corp.'s technological capabilities in AI-driven healthcare and biotech solutions. Adnexus is known for its groundbreaking work in AI-powered early drug discovery and infectious disease research, including HIV and SARS-COV-2 treatments.
The partnership would combine 1606 Corp.'s strengths in conversational AI and chatbot technology with Adnexus's innovative research efforts. Adnexus's unique methodology uses human "immune-B cells" from recovered individuals to create fully human monoclonal antibodies. The transaction is subject to due diligence and certain conditions. Both companies anticipate significant value creation for shareholders and technological advancement in their respective fields.
1606 Corp. (OTC Pink:CBDW), sviluppatore di tecnologie AI, ha firmato una lettera di intenti non vincolante (LOI) per acquisire una partecipazione strategica in Adnexus, una delle principali aziende biotech nel settore dell'AI. Questo investimento potenziale mira ad ampliare le capacità tecnologiche di 1606 Corp. nelle soluzioni sanitarie e biotech guidate dall'AI. Adnexus è conosciuta per il suo lavoro innovativo nella scoperta precoce di farmaci alimentata dall'AI e nella ricerca sulle malattie infettive, inclusi i trattamenti per HIV e SARS-COV-2.
La partnership combinerebbe i punti di forza di 1606 Corp. nell'AI conversazionale e nella tecnologia dei chatbot con gli sforzi di ricerca innovativi di Adnexus. Il metodo unico di Adnexus utilizza le
1606 Corp. (OTC Pink:CBDW), desarrollador de tecnología de IA, ha firmado una carta de intención no vinculante (LOI) para adquirir una participación estratégica en Adnexus, una empresa líder en biotecnología de IA. Esta potencial inversión tiene como objetivo expandir las capacidades tecnológicas de 1606 Corp. en soluciones de atención médica y biotecnología impulsadas por IA. Adnexus es conocida por su trabajo innovador en descubrimiento temprano de fármacos impulsado por IA e investigación sobre enfermedades infecciosas, incluidos los tratamientos para el VIH y SARS-COV-2.
La asociación combinaría las fortalezas de 1606 Corp. en IA conversacional y tecnología de chatbots con los esfuerzos de investigación innovadores de Adnexus. La metodología única de Adnexus utiliza
1606 Corp. (OTC Pink:CBDW), 인공지능 기술 개발업체, 는 주요 AI 생명공학 회사인 Adnexus의 전략적 지분을 인수하기 위한 비구속적 의향서(LOI)를 체결했습니다. 이 잠재적 투자는 AI 기반의 건강 관리 및 생명공학 솔루션에서 1606 Corp.의 기술 능력을 확장하는 것을 목표로 합니다. Adnexus는 AI 기반의 조기 약물 발견 및 감염병 연구, HIV 및 SARS-COV-2 치료에 대한 혁신적인 작업으로 알려져 있습니다.
이번 파트너십은 1606 Corp.의 대화형 AI 및 챗봇 기술의 강점과 Adnexus의 혁신적인 연구 노력을 결합하게 됩니다. Adnexus의 독특한 방법론은 회복된 개인의
1606 Corp. (OTC Pink:CBDW), développeur de technologies IA, a signé une lettre d'intention non contraignante (LOI) pour acquérir une participation stratégique dans Adnexus, une entreprise biotechnologique leader dans le domaine de l'IA. Cet investissement potentiel vise à élargir les capacités technologiques de 1606 Corp. en matière de santé et de solutions biotechnologiques basées sur l'IA. Adnexus est reconnue pour son travail révolutionnaire dans la découverte précoce de médicaments alimentée par l'IA et la recherche sur les maladies infectieuses, y compris les traitements du VIH et du SARS-COV-2.
Le partenariat combinerait les forces de 1606 Corp. en IA conversationnelle et en technologie de chatbot avec les efforts de recherche novateurs d'Adnexus. La méthodologie unique d'Adnexus utilise des « cellules B immunitaires » humaines de personnes guéries pour créer des anticorps monoclonaux entièrement humains. La transaction est soumise à une due diligence et à certaines conditions. Les deux entreprises anticipent une création de valeur significative pour les actionnaires et un avancement technologique dans leurs domaines respectifs.
1606 Corp. (OTC Pink:CBDW), ein Entwickler von KI-Technologien, hat ein unverbindliches Absichtsschreiben (LOI) unterzeichnet, um eine strategische Beteiligung an Adnexus, einem führenden KI-Biotech-Unternehmen, zu erwerben. Diese potenzielle Investition zielt darauf ab, die technologischen Fähigkeiten von 1606 Corp. im Bereich KI-gesteuerte Gesundheits- und Biotech-Lösungen auszubauen. Adnexus ist bekannt für ihre bahnbrechenden Arbeiten in der KI-unterstützten frühen Arzneimittelentdeckung und der Erforschung von Infektionskrankheiten, einschließlich HIV und SARS-COV-2-Behandlungen.
Die Partnerschaft würde die Stärken von 1606 Corp. in der konversationellen KI und der Chatbot-Technologie mit den innovativen Forschungsanstrengungen von Adnexus kombinieren. Die einzigartige Methodik von Adnexus verwendet menschliche „Immune-B-Zellen“ von genesenen Personen, um vollständig menschliche monoklonale Antikörper zu erzeugen. Die Transaktion unterliegt der Due Diligence und bestimmten Bedingungen. Beide Unternehmen erwarten eine signifikante Wertschöpfung für die Aktionäre und einen technologischen Fortschritt in ihren jeweiligen Bereichen.
- Potential expansion into AI-driven healthcare and biotech solutions
- Access to Adnexus's innovative AI technology for early drug discovery
- Possible synergies between 1606 Corp.'s AI expertise and Adnexus's biotech research
- Potential for accelerated innovation in healthcare sector
- LOI is nonbinding, acquisition not guaranteed
- Transaction subject to due diligence and undisclosed conditions
- Potential financial implications of the acquisition not disclosed
SEATTLE, WA / ACCESSWIRE / September 4, 2024 / 1606 Corp. (OTC Pink:CBDW), a leader in AI technology development, is pleased to announce that it has signed a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus, a pioneering company at the forefront of Artificial Intelligence innovations in early drug discovery and infectious disease research.
This potential strategic investment underscores 1606 Corp.'s commitment to expanding its technological footprint and enhancing its capabilities in the rapidly evolving field of AI. We believe the integration of Adnexus's cutting-edge AI research and development expertise would significantly bolster 1606 Corp.'s portfolio, bringing advanced solutions to the intersection of artificial intelligence and healthcare and biotech.
Adnexus has been recognized for its groundbreaking work in leveraging AI to drive early drug discovery and develop critical treatments for infectious diseases including HIV and SARS-COV-2. By aligning with Adnexus, 1606 Corp. aims to accelerate innovation and development within the healthcare sector, combining its strengths in conversational AI and chatbot technology with Adnexus's pioneering research efforts. For a deeper dive into Adnexus' groundbreaking technology, visit their website at www.adnexusbiotech.com.
Adnexus has distinguished itself in the field of biotechnology through its innovative approach to developing therapeutic solutions. Their proprietary methodology is centered around utilizing human "immune-B cells" sourced from individuals who have naturally recovered from target viruses. This unique process enables the creation of fully human monoclonal antibodies that exhibit natural affinity and specificity.
Austen Lambrecht, CEO of 1606 Corp., stated, "We are thrilled to enter into this agreement with Adnexus. Their exceptional work in AI-driven drug discovery and infectious disease treatment aligns perfectly with our vision of harnessing advanced AI technologies to create impactful solutions. This partnership represents a significant step forward in our strategy to diversify and enhance our technological capabilities."
The transaction is expected to be finalized following customary due diligence and the fulfillment of certain conditions as stated in the LOI. Both companies anticipate that this strategic alignment will generate significant value for shareholders, advance technological development, and drive innovation in their respective fields.
CEO, Austen Lambrecht and 1606 Corp. (CBDW) are glad to announce that we will be presenting at the 150th NIBA Show in Fort Lauderdale on Thursday, August 5th.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
Industry Information
The global artificial intelligence market has seen remarkable growth, valued at
Forward-Looking Statements
This press release includes statements that may be deemed to be "forward-looking statements" under federal securities laws, and we intend that such forward-looking statements be subject to the safe-harbor created thereby. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as "should", "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." Specific forward-looking statements in this press release include, among others, statements regarding the expected trading of our shares on The Nasdaq Capital Market, the expected closing of the offering, and the intended use of the net proceeds of the offering. Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially and adversely from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in the prospectus included in the Registration Statement and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and 1606 Corp. does not undertake any duty to update any forward-looking statements except as may be required by law. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
For inquiries, please contact:
Austen Lambrecht
CEO
austen@1606corp.com
cbdw.ai
SOURCE: 1606 Corp.
View the original press release on accesswire.com
FAQ
What is the purpose of 1606 Corp.'s (CBDW) acquisition of Adnexus?
What is Adnexus known for in the biotech industry?
How might this acquisition benefit 1606 Corp. (CBDW) shareholders?
Is the acquisition of Adnexus by 1606 Corp. (CBDW) finalized?
